Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
According to a new report published in JAMA Oncology, women with BRCA1 mutations have a higher risk of developing an aggressive type of uterine cancer.
$4 million grant gives Columbia, Weill Cornell Medicine, NewYork-Presbyterian, and NYC Health + Hospitals key role in precision medicine cohort program.
Cancer centers announce the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.
An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA levels who had more aggressive disease.
A Super Bowl ad has launched a new campaign at NewYork-Presbyterian Hospital that showcases Columbia and Weill Cornell expertise in cancer, particularly immunotherapy.